Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

Commercial sponsorship integrates EvE Bio's growing field‑defining "pharmome" map - 385,572 rigorously confirmed drug–target interactions across 159 validated targets - into DrugBank's intelligence ...

Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally NEW ORLEANS, [November 14, 2024] — In a landmark continuing ...

NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...

Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...

CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced its ...